Recent strategies to improve boron dipyrromethene (BODIPY) for photodynamic cancer therapy: an updated review

Kue CS 1 , Ng SY 2 , Voon SH 3 , Kamkaew A 4 , Chung LY 2 , Kiew LV 5 Show all authors , Lee HB 2

Affiliations 

  • 1 Department of Diagnostic and Allied Health Sciences, Faculty of Health and Life Sciences, Management & Science University, 40100 Shah Alam, Selangor, Malaysia. hongboonlee@um.edu.my hongboonlee@gmail.com
  • 2 Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. chungly@um.edu.my chungly@hotmail.com
  • 3 Project Leadership, Clinical Operations, R&D Solutions, IQVIA, 50480 Kuala Lumpur, Malaysia
  • 4 School of Chemistry, Institute of Science, Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand
  • 5 Department of Pharmacology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
Photochem Photobiol Sci, 2018 Nov 01;17(11):1691-1708.
PMID: 29845993 DOI: 10.1039/c8pp00113h

Abstract

BODIPYs are photosensitizers activatable by light to generate highly reactive singlet oxygen (1O2) from molecular oxygen, leading to tissue damage in the photoirradiated region. Despite their extraordinary photophysical characteristics, they are not featured in clinical photodynamic therapy. This review discusses the recent advances in the design and/or modifications of BODIPYs since 2013, to improve their potential in photodynamic cancer therapy and related areas.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications